Hyman, Phelps & McNamara, P.C.’s David B. Clissold has been named to the Board of Advisors of Analgesic Clinical Trial Innovations, Opportunities, and Networks (“ACTION”). ACTION is a public-private partnership aligned with FDA’s recently launched Initiative for the Advancement of Regulatory Science. ACTION is designed to benefit the public health by streamlining the discovery and development process for new analgesic medications. More information about the ACTION Initiative is available here and here. FDA will make study results, best practices, and outcomes of the ACTION Initiative available on the Agency’s website (here) as they are developed.